476 related articles for article (PubMed ID: 32388458)
1. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Rejdak K; Grieb P
Mult Scler Relat Disord; 2020 Jul; 42():102163. PubMed ID: 32388458
[TBL] [Abstract][Full Text] [Related]
2. What can Parkinson's disease teach us about COVID-19?
Tipton PW; Wszolek ZK
Neurol Neurochir Pol; 2020; 54(2):204-206. PubMed ID: 32323862
[No Abstract] [Full Text] [Related]
3. Response to "Does amantadine have a protective effect against COVID-19?".
Tipton PW; Wszolek ZK
Neurol Neurochir Pol; 2020; 54(3):286-287. PubMed ID: 32583401
[No Abstract] [Full Text] [Related]
4. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
5. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
[TBL] [Abstract][Full Text] [Related]
6. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
7. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
8. Potential for the Repurposing of Adamantane Antivirals for COVID-19.
Butterworth RF
Drugs R D; 2021 Sep; 21(3):267-272. PubMed ID: 34152583
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
10. [COVID-19: A neurological point-of-view].
Simon OJ; Timmermann L
Dtsch Med Wochenschr; 2020 Jul; 145(15):1074-1079. PubMed ID: 32731282
[TBL] [Abstract][Full Text] [Related]
11. Does amantadine have a protective effect against COVID-19?
Cortés Borra A
Neurol Neurochir Pol; 2020; 54(3):284-285. PubMed ID: 32495926
[No Abstract] [Full Text] [Related]
12. Spectrum of Neurological Manifestations in Covid-19: A Review.
Garg RK
Neurol India; 2020; 68(3):560-572. PubMed ID: 32643664
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis following SARS-CoV-2 infection.
Palao M; Fernández-Díaz E; Gracia-Gil J; Romero-Sánchez CM; Díaz-Maroto I; Segura T
Mult Scler Relat Disord; 2020 Oct; 45():102377. PubMed ID: 32698095
[TBL] [Abstract][Full Text] [Related]
14. Neurological manifestations of COVID-19.
Kanwar D; Baig AM; Wasay M
J Pak Med Assoc; 2020 May; 70(Suppl 3)(5):S101-S103. PubMed ID: 32515379
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 and smoking: a high-risk association.
Silva ALOD; Moreira JC; Martins SR
Cad Saude Publica; 2020; 36(5):e00072020. PubMed ID: 32428076
[No Abstract] [Full Text] [Related]
16. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
Zhang JJ; Dong X; Cao YY; Yuan YD; Yang YB; Yan YQ; Akdis CA; Gao YD
Allergy; 2020 Jul; 75(7):1730-1741. PubMed ID: 32077115
[TBL] [Abstract][Full Text] [Related]
17. Rehabilitation Recommendations for Multiple Sclerosis Patients during the COVID-19 Pandemic.
Naser Moghadasi A; Azadvari M; Sahraian MA
Arch Iran Med; 2020 Jul; 23(7):509-510. PubMed ID: 32657605
[No Abstract] [Full Text] [Related]
18. Heralding Healthcare Professionals: Recognition of Neurological Deficits in COVID-19.
Baig AM; Sanders EC
ACS Chem Neurosci; 2020 Jun; 11(12):1701-1703. PubMed ID: 32469504
[TBL] [Abstract][Full Text] [Related]
19. Amantadine, COVID-19 and Parkinsonism.
Wiwanitkit V
Arch Med Res; 2020 Oct; 51(7):714. PubMed ID: 32660794
[No Abstract] [Full Text] [Related]
20. Response to: Amantadine, COVID-19 and Parkinsonism.
Aranda-Abreu GE
Arch Med Res; 2020 Oct; 51(7):715. PubMed ID: 32723524
[No Abstract] [Full Text] [Related]
[Next] [New Search]
